Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Approved building permission for Hynion's hydrogen refueling station in Västerås

The building committee in Västerås has decided to grant Hynion a building permit for the new construction of a hydrogen refueling station at the STOP128 truck stop in Västerås. It is one of two stations for which Hynion has been granted a grant from the Swedish Energy Agency and which is to be completed in January 2024.As previously communicated, Hynion has been granted a grant of SEK 61.4 million from the Swedish Energy Agency to build two hydrogen refueling stations with a capacity of 1,500 kg of hydrogen per day. One station is to be built in Västerås, at the STOP128 truck stop, right

Carbonhand is available for Veterans in the US

Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function.[Carbonhand hjlper till i vardagen] Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle,

Coor signs agreement with Swedbank

Coor signs an Integrated Facility Management agreement (IFM) with Swedbank. The agreement spans four years with an option to extend it and has an annual contract value of some SEK 220 M including an estimate of annual variable volumes.Coor’s assignment entails broad integrated service delivery including cleaning, technical services, administrative services, coffee, fruit, plants, and janitorial services in Swedbank’s all offices across Sweden. The assignment starts on 15 December 2023. “The new IFM assignment is a partnership agreement that we developed together, and our company cultures

Inhalation Sciences AB (publ) releases Q2 Report 2023

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q2 Report for 2023 is now available on the company’s website.To read the whole report (in Swedish) visit: http://inhalation.se/investors/finansiella-rapporter/ CEO statement During the second quarter, we have continued to deliver on our strategic goals with a focus on commercial activities, where revenue has increased by 36% compared to the same period last year. Sales in the form of new signed orders have also continued in the right direction with an increase of over 500% compared to the same period last

Interim Report Q2 – April – June, 2023 Redsense Medical AB (publ)

APRIL – JUNE 2023 · Net sales amounted to kSEK 4,831 (1,927), an increase of 151%. · Operating loss, EBIT amounted to kSEK 3,045 (2,428). · Result after tax amounted to kSEK -2,966 (-2,137). · Earnings per share were SEK -0.21 (-0.15). SIGNIFICANT EVENTS DURING THE PERIOD · On April 28, Redsense announced that Redsense and FDA held a Pre-Submission Meeting in preparation for the 510(k) Premarket Submission of the Redsense Clamp. · On May 8, Redsense announced that the Home Dialysis Risk Prevention Act was introduced by the US House of Representatives. · On June

BioStock: Aqilion takes aim at eosinophilic esophagitis with AQ280

Eosinophilic esophagitis is a challenging chronic inflammatory condition. Often leading to painful swallowing and food impaction, which can be fatal, EoE represents a significant area of unmet medical need where effective treatments are lacking. Enter Aqilion, who have just completed a phase I study with their candidate AQ280. BioStock spoke with CEO Sarah Fredriksson to learn more about the candidate and its potential in EoE management.Read the interview with Aqilion's CEO Sarah Fredriksson at biostock.se: https://www.biostock.se/en/2023/08/aqilion-tar-sikte-pa-eosinofil-esofagit-med-

Finnish startup Videobot secures €2M funding to revolutionize online customer experiences with interactive video chatbots

Founded in 2022, the fast-growing startup harnesses the increasing popularity of video content to augment traditional website experiences. Videobot already has over 200 customers in 15 countries, including game giant Supercell.TURKU, Finland (August 29th, 2023) Videobot , a Finnish SaaS startup, has successfully raised €2 million in seed funding from Finland’s Superhero Capital, Luxembourg’s Expon Capital Digital Tech Fund, and angel investors, Sweden’s Urban Gillstrom and Finland’s Ari Korhonen. The company aims to transform the landscape of online customer

BioStock: Aqilion Takes Aim at Eosinophilic Esophagitis with AQ280

Eosinophilic esophagitis is a challenging chronic inflammatory condition. Often leading to painful swallowing and food impaction, which can be fatal, EoE represents a significant area of unmet medical need where effective treatments are lacking. Enter Aqilion, who have just completed a phase I study with their candidate AQ280. BioStock spoke with CEO Sarah Fredriksson to learn more about the candidate and its potential in EoE management.Read the interview with Sarah Fredriksson at biostock.se: Aqilion Takes Aim at Eosinophilic Esophagitis with AQ280 - BioStock 

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023

Second quarter (April-June 2023) · Operating profit/loss totaled SEK -4,466,286 (-3,641,800). · Loss for the period totaled SEK -4,335,852 (-3,667,200). · Cash flow from operating activities totaled SEK -2,146,178 (-3,877,975). · Earnings per share before dilution totaled SEK -0.22 (-0.19). Earnings per share after dilution amounted to SEK - 0.22 (-0.19).   Period (January-June 2023) · Operating profit/loss totaled SEK -6,732,143 (-8,382,851). · Loss for the period totaled SEK -6,602,181 (-8,421,815). · Cash flow from operating activities totaled SEK -4,181,

Faron 2023 Half-Year Financial Results

Faron Pharmaceuticals Ltd. (“Faron” or “the Company”)   Faron Reports Half-Year Financial Results, January 1 – June 30, 2023   Company Announcement, August 29, 2023   Summary Highlights (including post-period events)     · The US Food and Drug Administration (FDA) granted bexmarilimab Orphan Drug Designation (ODD) for the treatment of acute myeloid leukemia (AML). · The latest data from the Phase I/II BEXMAB study reinforces bexmarilimab’s potential to improve the therapeutic benefit for patients with aggressive hematological malignancies who do not respond

Repurchases of shares by Concentric AB during week 34, 2023

Between 21 August 2023 and 25 August 2023 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 29,468 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

Q2 and half year report January – June 2023

Strengthening of management & acquisition in RomaniaHighlights second quarter 2023 · Cash at the end of June 2023 was EUR 32.2m (52.3 at December 2022) · Gross ERC at the end of June 2023 was EUR 255m (283 at December 2022) · Sale of 5% stake in Borgosesia S.p.A (pending regulatory approval) and associated NPL portfolio due to continuous active asset management · Gross collections amounted to EUR 20.3m (15.5)* · Net collections amounted to EUR 18.4m (13.4)* · Cash EBITDA amounted to EUR 13.8m (10.8)* · Net profit for the period of EUR 1.0m (loss of 3.6) Highlights

Q2 and half year report January – June 2023

Strengthening of management & acquisition in RomaniaHighlights second quarter 2023 · Cash at the end of June 2023 was EUR 32.6m (52.6 at December 2022) · Gross ERC at the end of June 2023 was EUR 256m (284 at December 2022) · Sale of 5% stake in Borgosesia S.p.A (pending regulatory approval) and associated NPL portfolio due to continuous active asset management · Gross collections amounted to EUR 20.5m (15.8)* · Net collections amounted to EUR 18.6m (13.8)* · Cash EBITDA amounted to EUR 11.7m (10.9)* · Net loss for the period of EUR 1.7m (loss of 4.2) Highlights

Arctic Bioscience – HeROPA study recruitment progressing well and strong nutra revenue growth

Highlights H1 2023: · The phase IIb HeROPA clinical trial for treatment of patients with mild-to-moderate psoriasis approved by Medicines Authorities in all the five European countries and recruiting is progressing well. Read-out expected in H1 2024 · Solid financial position with available liquidity totaling NOK 113,8 million by end of H1 2023. Current financing sufficient throughout read-out for the HeROPA clinical trial · Solid growth in the Nutra-segment with an increase of total revenues by 33 % y/y to NOK 19,1 million (NOK 14,4 million) in H1 2023. Revenue prospects for H2

BPC Instruments reports half-year and second quarter results 2023

BPC Instruments (“BPC” or “the Company”) hereby publishes the half-year report for the period January 1 – June 30, 2023. The half-year report is available as an attached file to this release and on the Company’s website (bpcinstruments.com/financial-reports). Below is a summary of the report.CEO Dr. Jing Liu comments: “I am proud to share that the second quarter of 2023 has been another strong period for BPC, building on the momentum from our record-breaking first quarter. Our net sales reached a solid KSEK 10,598, representing a 27 percent increase compared to the same quarter last year.

Borr Drilling Limited – Announcement of Letter of Award

Borr Drilling Limited (the “Company”) (NYSE and OSE: “BORR”) is pleased to announce that its premium jack-up rigs “Prospector 5” and “Natt” have received a Letter of Award (“LOA”) for work in West Africa in direct continuation of their current contracts. The contracts will have a combined duration of 1,307 days and a total estimated contract value is $211 million. Under this LOA, the “Prospector 5” and “Natt” will remain contracted until May 2026 and December 2025, respectively. Hamilton, Bermuda 29 August 2023 Forward looking statements This press release includes forward

Juha Markkanen appointed as new CEO of Knowit Solutions Oy

Juha Markkanen (B.Sc) has been appointed as the new CEO of Knowit Solutions Oy, starting from 1st of September 2023.Markkanen, who has a long career in management, sales and development positions in the IT industry, will become CEO from the position of Chief Operating Officer of Knowit Solutions Oy. Previously he has worked in the company e.g. as Vice President of Sales and Marketing and acting CEO. - I take on the CEO role excited and proud of how I have managed to plan and build Knowit Solutions of the future in my current role. Our great success in our challenging market situation at

Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

Uppsala, Sweden – August 29, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the amorphOX® drug delivery platform.   Orexo continues to strengthen its patent portfolio and the new patent, No. US 11,737,980, provides protection for the OX640 product in the US until May 2041. Last year, a European patent was granted, and multiple patent applications have been filed by Orexo protecting OX640 on a

IFA 2023: Electrolux Group puts the spotlight on energy efficiency with AEG EcoLine

Global appliance company Electrolux Group – under its premium brand AEG – is showcasing the AEG EcoLine, for the first time, at IFA 2023. AEG EcoLine is a dedicated selection, presented in-store and online, of some the company’s most energy efficient kitchen and laundry appliances, and most efficiently performing home care appliances aimed at helping consumers to reduce climate impact while providing high-quality performance. The selection of appliances from the current AEG and Electrolux portfolio as well as the new AEG SaphirMatt induction hob with scratch-resistant glass will be revealed

Polymers as carbon storage: Neste, LyondellBasell, Biofibre and Naftex bring bio-based polymers to the construction sector

Neste Corporation, Press Release, 29 August 2023 at 9 a.m. (EET)  Photo: Posts for fences made of natural fiber reinforced plastics. Source: Naftex. · Cooperation enables construction parts to be made of bio-based plastics reinforced with natural fiber  · Longevity of construction materials can enable storing of carbon for years or even decades Neste, LyondellBasell, Biofibre and Naftex have created a value chain to combine bio-based polymers with natural fiber for the manufacturing of construction elements. The combination of polymers with measurable bio-based content

Peab builds hospital in Vaasa

Peab has been commissioned to build a forensic psychiatric hospital with 48 care units in Vaasa. The customer is Senate Properties and the contract is worth EUR 26 million.The project entails building a new 5,500 m2 two story building at Vaasa Hospital. The work will begin by demolishing the old hospital building to make room for the new one. The new building will contain the hospital’s three most highly secure sections as well as a multi-functional room, a kitchen and a staff dining room. In designing the building, which will be built in the culturally historic city borough Vanha Vaasa,

New report from Essity links gender equality to global health and well-being

Women’s health issues continue to be overlooked in society. This is one of several findings in Essity’s Health and Hygiene Report 2023-2024, linking gender equality, care, and prevention to personal well-being and public progress, emphasizing the need for joint action to effect change.The Hygiene and Health Report 2023-2024: Advancing Health and Well-being through Care, Prevention, and Gender Equality , published by the global hygiene and health company Essity, demonstrates how

FDA Orphan Drug Designation for Bexmarilimab

Faron Pharmaceuticals Ltd. (“Faron” or “the Company”)    Inside Information:  Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia   · ODD further strengthens bexmarilimab program by offering clinical development and commercialization benefits · Expected completion of dose escalation, readout of enrichment cohorts, and Phase II initiation in Q4 2023   Company Announcement, August 29, 2023   Inside Information   TURKU, Finland / BOSTON, Massachusetts – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-

Elkem accelerates maintenance in Iceland

Elkem has decided to accelerate maintenance at its plant in Iceland. The accelerated maintenance will curtail production by temporarily shutting down one furnace at the ferrosilicon plant in Grundartangi, about 40 kilometres from the capital Reykjavik. The decision will have no impact on customers or employees.“We continue to utilise a period with somewhat lower sales to bring forward planned maintenance and improvement work to position for the future, now at our plant in Iceland. This will enable lower production costs once stronger market conditions return,” says Elkem’s senior vice

There are no items matching the current filter
There are no more items matching the current filter
Back to top